- ESMO data demonstrate breadth of joint Regeneron and Sanofi immuno-oncology development program
- ESMO presentations follow the recent U.S. FDA approval of Libtayo for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation
PR Newswire
TARRYTOWN, N.Y. and PARIS, Oct. 8, 2018